Abstract
Objective: We evaluated if urinary excretion of kallikrein and kallistatin (a glandular kallikrein inhibitor) is altered early during gestation in patients who will ultimately develop pregnancy-induced hypertension.Methods: The protocol was designed as a nested, longitudinal case-control study. Overnight urine collections were obtained at 12-20, 24-26, and 30-32 weeks of gestation in a consecutive series of 350 primigravidae. Urinary kallikrein (amidolytic assay) and kallistatin (enzyme-linked immunosorbent assay) levels were measured in all patients (n = 24) who were found to be affected by pregnancy-induced hypertension. In addition, urinary kallikrein and kallistatin levels were measured in 24 women used as controls. They were chosen from the group of 326 normotensive subjects by matching them with the hypertensive patients for age and gestational time at the occasion of urine collections.Results: Prevalence of pregnancy-induced hypertension with or without proteinuria was 2.3% and 4.6%, respectively. ...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
